title: [Transdermal fentanyl for the management of cancer pain: a survey of 4492 patients].
abstract: OBJECTIVE
  To evaluate the efficacy and adverse effects of transdermal fentanyl in management of patients with cancer pain.
  
  
  METHODS
  A total of 4492 patients (aged 3-90) with cancer pain were enrolled in this multicenter study. The mean age was 58.5 (3 approximately 90) years old. All patients received transdermal fentanyl. The patients were asked to record the attacks of pain, quality of life, and any side effects of the treatment.
  
  
  RESULTS
  Baseline mean pain intensity was 7.37. On days 1, 3, 6, 9, 15, and 30, the mean scores of pain were decreased to 4.04, 2.98, 2.52, 2.19, 1.85 and 1.61, respectively (P < 0.01). The effective rate was 96.8%. The mean doses of fentanyl were 32.37 microg/h (25-200 microg/h) on the initial day, 42.57 microg/h and 49.57 microg/h (25-225 microg/h) on days 15 and 30. The quality of life was significantly improved after treatment (P < 0.01). The common side effects were constipation (9.8%), nausea (13.6%), dizziness (6.5%), vomiting (3.9%), sedation (2.0%) and respiratory depression (0.2%). The incidence of constipation was related to age, and the incidence of vomiting and difficulty of urination was related to gender. The majority (84.5%) of patients preferred continuation of the treatment with transdermal fentanyl.
  
  
  CONCLUSIONS
  Transdermal fentanyl for the patients with cancer pain is effective, safe, convenient and can improve the quality of life. Transdermal fentanyl can be recommended as one of first-line drugs for the treatment of patients with moderate to severe cancer pain.
authors.affiliation: Cancer Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Techenology, Wuhan 430030, China. syyu@tjh.tjmu.edu.cn
authors.forename: Shi-ying
authors.initials: SY
authors.lastname: Yu
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun
authors.forename: Yi-long
authors.initials: YL
authors.lastname: Wu
authors.forename: Shu-kui
authors.initials: SK
authors.lastname: Qin
authors.forename: Guang-ru
authors.initials: GR
authors.lastname: Xie
authors.forename: Shu-jun
authors.initials: SJ
authors.lastname: Liu
authors.forename: Guang-jie
authors.initials: GJ
authors.lastname: Sui
authors.forename: Hai-chun
authors.initials: HC
authors.lastname: Zhang
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D004067:Digestive System Neoplasms / Q000150:complications; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010148:Intractable Pain / Q000188:drug therapy* / Q000209:etiology; D011788:Quality of Life
chemical_list: D000701:Analgesics, Opioid; D005283:Fentanyl